Curanex Pharmaceuticals Inc (NASDAQ:CURX) Short Interest Update

Curanex Pharmaceuticals Inc (NASDAQ:CURX) was the target of a large decline in short interest during the month of July. As of July 15th, there was short interest totaling 11,829 shares, a decline of 43.2% from the June 30th total of 20,835 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily volume of 81,338 shares, the short-interest ratio is currently 0.1 days.

Hedge Funds Weigh In On Curanex Pharmaceuticals

An institutional investor recently bought a new stake in Curanex Pharmaceuticals stock. Citadel Advisors LLC acquired a new stake in shares of Curanex Pharmaceuticals Inc (NASDAQ:CURX) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 64,067 shares of the company’s stock, valued at approximately $46,000.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Curanex Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Curanex Pharmaceuticals Stock Performance

CURX stock traded down $0.01 during mid-day trading on Wednesday, hitting $0.19. The company had a trading volume of 12,197 shares, compared to its average volume of 1,939,257. The firm has a market cap of $5.45 million and a PE ratio of -0.71. Curanex Pharmaceuticals has a 12 month low of $0.18 and a 12 month high of $9.18. The stock’s fifty day moving average price is $0.27 and its two-hundred day moving average price is $0.35.

Curanex Pharmaceuticals (NASDAQ:CURX) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.11) EPS for the quarter.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.